ReCode Therapeutics

ReCode Therapeutics ReCode Therapeutics is a clinical-stage genetic medicines company powering the future of genetic medicines with precision delivery.

Vladimir Kharitonov, Ph.D., brings more than two decades of experience in pharmaceutical development to his role as SVP ...
04/11/2026

Vladimir Kharitonov, Ph.D., brings more than two decades of experience in pharmaceutical development to his role as SVP of CMC and Pharmaceutical Sciences at ReCode. His work spans early formulation design to clinical manufacturing, reparation of INDs, IMPDs, NDAs MAAs, and commercial manufacture with each step grounded in precision, accountability, and long-term impact.

Today, Vlad reflects on how careful decision-making and long-term thinking help build trust in each study.

Heather Clark, M.S., Senior Vice President and Head of Cystic Fibrosis Franchise, brings both expertise and continuity t...
04/03/2026

Heather Clark, M.S., Senior Vice President and Head of Cystic Fibrosis Franchise, brings both expertise and continuity to ReCode’s work in CF. Her decades of experience are shaped by long-standing connections with individuals and families affected by the disease.

Here, Heather reflects on what drives her commitment to advancing treatment options for the CF community. Her approach is informed by real relationships, a deep understanding of the science, and a clear goal: expand access to effective therapies for those who need them most.

03/28/2026

In this video, our Chief Scientific Officer Jessica Couch shares how a translational mindset guides her team’s work from discovery through clinical trials.

Her approach centers on integrating data and clinical insight at every stage of development, with decisions made to support safe and responsible progress toward potential therapies for people living with genetic diseases.

Are you over 18 and living with cystic fibrosis (CF)? You may qualify for our Phase 2 clinical trial evaluating RCT2100,...
03/05/2026

Are you over 18 and living with cystic fibrosis (CF)? You may qualify for our Phase 2 clinical trial evaluating RCT2100, an investigational inhaled CFTR mRNA therapy in combination with ivacaftor.

Learn more about this opportunity to participate in CF research and help inform the future of care by visiting the link in our bio.

ReCode’s clinical study for cystic fibrosis uses an investigational inhaled mRNA therapy, RCT2100, evaluated in combinat...
03/03/2026

ReCode’s clinical study for cystic fibrosis uses an investigational inhaled mRNA therapy, RCT2100, evaluated in combination with ivacaftor, to address CF at its genetic roots. This approach leverages our Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform to enable targeted delivery to lung cells.

Learn how we’re helping to meet this unmet need with a new clinical study at the link in our bio.

Every clinical study brings cystic fibrosis research closer to new possibilities for treatment. CF affects more than jus...
02/16/2026

Every clinical study brings cystic fibrosis research closer to new possibilities for treatment. CF affects more than just the lungs; it impacts the digestive system and other organs, including the liver, pancreas, and reproductive system, and can touch nearly every part of daily life for those affected.

By joining ReCode’s Phase 2 clinical study evaluating RCT2100, an investigational inhaled CFTR mRNA therapy in combination with ivacaftor, participants contribute to research that helps advance understanding of CF and informs future development for the CF community.

See how participation makes a difference at the link in our bio.

Partnership has been central to every major advancement in cystic fibrosis care, and Heather L. Clark has spent her care...
02/12/2026

Partnership has been central to every major advancement in cystic fibrosis care, and Heather L. Clark has spent her career proving it. As Senior Vice President, CF Franchise & Head of the Program Management Office, she emphasizes that our collaboration with the Cystic Fibrosis Foundation, investigators, and families is essential to moving research forward.

These partnerships are the backbone of our work on RCT2100, an investigational inhaled CFTR mRNA therapy currently being evaluated in a Phase 2 clinical study in combination with ivacaftor, and support the generation of data to inform future development.

Learn more about how clinical research and community collaboration continue to shape the future of CF treatment at the link in our bio.

Clinical research for cystic fibrosis depends on the strength of the CF community. Every participant, caregiver, and hea...
02/10/2026

Clinical research for cystic fibrosis depends on the strength of the CF community. Every participant, caregiver, and healthcare provider plays a role in advancing research. ReCode’s Phase 2 clinical study is evaluating RCT2100, an investigational inhaled CFTR mRNA therapy, in combination with ivacaftor in people with CF.

Together with the CF community, this research helps generate data to inform future development efforts.

For more information, visit the link in our bio.

02/05/2026

ReCode CEO Dr. Shehnaaz Suliman discusses how RCT2100, an investigational inhaled CFTR mRNA therapy, is being studied for people with cystic fibrosis (CF) who have limited treatment options. This includes individuals who do not benefit from currently available CFTR modulators due to their inability to produce functional CFTR protein.

RCT2100 is being evaluated in a Phase 2 clinical trial in combination with ivacaftor. Watch to learn more about the study and how ongoing research aims to address unmet needs within the CF community.

Learn how we’re helping to meet this unmet need with a new clinical study at the link in our bio.

Are you over 18 and living with cystic fibrosis (CF)? You may qualify for our Phase 2 clinical trial evaluating RCT2100,...
02/04/2026

Are you over 18 and living with cystic fibrosis (CF)? You may qualify for our Phase 2 clinical trial evaluating RCT2100, an investigational inhaled CFTR mRNA therapy in combination with ivacaftor.

Learn more about this opportunity to participate in CF research and help inform the future of care by visiting the link in our bio.

Are you ready to help advance cystic fibrosis research? ReCode’s clinical study of RCT2100, an investigational inhaled C...
01/30/2026

Are you ready to help advance cystic fibrosis research? ReCode’s clinical study of RCT2100, an investigational inhaled CFTR mRNA therapy evaluated in combination with ivacaftor, is designed for individuals with CF. With options such as at-home dosing (where available) and travel support, the study is structured to help reduce barriers to participation.

Participation may help support research evaluating the safety and tolerability of this investigational approach and inform future development efforts.

Learn more about the clinical trial and investigational therapy via the link in our bio.

ReCode’s clinical study for cystic fibrosis uses an investigational inhaled mRNA therapy, RCT2100, evaluated in combinat...
01/28/2026

ReCode’s clinical study for cystic fibrosis uses an investigational inhaled mRNA therapy, RCT2100, evaluated in combination with ivacaftor, to address CF at its genetic roots. This approach leverages our Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform to enable targeted delivery to lung cells.

Learn how we’re helping to meet this unmet need with a new clinical study at the link in our bio.

Address

1140 O'Brien Drive
Menlo Park, CA
94025

Telephone

+14085851700

Website

Alerts

Be the first to know and let us send you an email when ReCode Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ReCode Therapeutics:

Shortcuts

Share

Category